STEM CELL LAB DEVELOPMENT AGREEMENT

 

 This STEM CELL LAB DEVELOPMENT AGREEMENT (this “Agreement”) made the 6th day of
July, 2017 , by and between DaVinci Centre for Wellness and Alternative
Therapies, formed and organized under the laws of the Cayman Islands
(“DaVinci”), Halo Cell Sciences, Ltd, a Cayman Islands corporation (“Cell
Sciences”), and Vitro Diagnostics, Inc., a Nevada corporation (“Vitro”).
DaVinci, Cell Sciences, and Vitro are sometimes referred to herein collectively
as the “Parties ” and each individually as a “Party.” This signed Stem Cell
Development Agreement shall become effective upon the minimum sufficient funding
in the amount of $1,500,000 being raised by Vitro and the completion of the
items detailed in the “Terms of Agreement” laid out below. 

 

RECITALS

 

 WHEREAS, Vitro and Cell Sciences plan to develop and operate a fully
functioning  stem cell laboratory on Grand Cayman (the “Lab”); 

 

 WHEREAS, DaVinci has agreed to provide services in connection with the creation
and operation of the Lab as described herein.   

 

 NOW, THEREFORE, in consideration of the mutual premises and covenants set forth
herein and other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the parties hereby agree as follows. 

 

1.   Services to Be Provided By DaVinci.  In connection with the development and
operation of the Lab, DaVinci agrees to provide the following consulting and
support services (the “Services”) to Cell Sciences, on an on-going and as-needed
basis: 

 

 a. Licensed and Registered Healthcare Facility (DaVinci Centre Cayman Islands)
Health Practice Commission of the Cayman Islands, for Stem Cell Transplant.   

 

 b.  Staffing of qualified and registered healthcare personnel for the
     transplant of autologous or allogeneic MSC at the Da Vinci Wellness
Centre. 

 

 c.  Patient Customer Service, screening, eligibility, support and follow up
with respective international physicians. 

 

 d. Institutional Review Board (“IRB”) Approval for the use of fat derived
autologous MSC for the clinical trial for the medical condition of multiple
sclerosis, pending the transfer of the present IRB to include Vitro as the
laboratory expanding cells, and submission of the Standard Operating Procedures
(“SOP”) of Vitro. 

 

 e.  Institutional Review Board (IRB) Approval for the use of fat derived
autologous MSC or Allogeneic Cells for the clinical trial regarding chronic low
grade inflammation and stem cells as an immune modulator targeting inflammation,
pending the transfer of the present IRB to Vitro as the laboratory for cell
expansion, and submission the SOPs of Vitro. 

 

 f. Future IRB approved clinical trials, on an on-going basis. 

--------------------------------------------------------------------------------

 g.  Collaborate with Vitro, on an on-going basis, to create new and innovative
clinical and scientific applications. 

 

 h.  Approved Certification to engage in clinical trials using autologous and
allogeneic MSC (Cayman Islands) for both the Health Facility (The DaVinci
Centre) and DaVinci Cayman Islands Registered Physicians. 

 

 i. Consulting and Support of newly established Stem Cell Laboratory, with
Senior Managerial Control/ Oversight of the day-to-day operations (in
collaboration with Cell Sciences executive staff). 

 

 j. Medical Directorship, as per Health Practice Commission of the Cayman
Islands Regulations, for the applications and operation of a Registered Cayman
Islands Health Facility (stem cell lab). 

 

 k.  Consult and support for marketing and promotion of a cellular therapy
entity.(name to be determined) in collaboration with Cell Sciences executive
staff. 

 

 l.  Consult and support for the development and marketing of nutraceutical
products in collaboration with Cell Sciences executive staff. 

.

2.   Term of Agreement. This Agreement shall commence on the Effective Date set
forth above and continue for a period of ten (10) years, unless sooner
terminated as provided herein (the “Term”). The Effective Date of this Agreement
shall be simultaneous to the date that Vitro consummates an equity funding in an
amount not less than $1.5 million and is contingent upon the completion of the
following items: 

 

 a. Halo Cell Science, ( or name to be determined),  will operate under the
direction/supervision of Da Vinci Management/Board of Directors and all
operational decisions would be subject to approval by the CEO of Da Vinci. Da
Vinci shall have the right, at its expense, to inspect and audit the books and
records of Halo Cell Science to confirm such information. 

                       b.  A separate governing Board of Directors belonging to
and provided full oversight/day-to-day control over Halo Cell Sciences, Ltd.
Control including, but not limited to, Cell Sciences marketing, hiring,
administrative, and financial decisions in the Cayman Islands. The board will
consist of two positions to be nominated by Vitro, two positions to be nominated
by DaVinci, and one Chairman. The CEO of Da Vinci will reserve the discretionary
right to have the casting vote/Tie-Breaker position.  

 

 c.     Frank Cona be appointed in a salaried position as CEO, and Chairman of
the Board of Cell Sciences to oversee all operations within the Cayman Islands.(
in Accordance with section 2.a under Terms of Agreement). In addition, Frank
Cona be appointed on the Board of Directors of Vitro to serve as the link
between Vitro and Cell Sciences.   

--------------------------------------------------------------------------------

 d.     One-time transfer of raised funds to Cell Sciences from Vitro for the
purpose of completing an initial marketing/advertising campaign, hiring of
employees, setup of the Lab, and associated fees. The amount of funds
transferred will be in accordance with projections of said items at the time of
execution and agreed upon before this agreement goes into effect.  

                      e. Vitro/ Halo Cell Science agrees to pursue and execute
the concept of creating a fully functional stem cell laboratory on Grand  Cayman
(the “Lab”) within one year of signing this agreement;

 

3.   Fees. In consideration of the Services to be provided by DaVinci hereunder,
Cell Sciences and Vitro shall pay to DaVinci the following fees:  

 

 a.  As a one-time retainer fee, Vitro shall issue to DaVinci such number of
shares of a newly declared series of Vitro preferred stock that shall convert,
at the holder’s option, into a total 21,000,000 shares of Vitro common stock
(the “Retainer Shares”).  The Retainer Shares shall be subject to vesting as set
forth below.  The certificate of designation for the preferred shares will
contain customary anti-dilution protection for stock splits, dividends and the
like. 

 

 b. As further consideration for providing the on-going Services provided by
DaVinci, DaVinci shall pay to Cell Sciences an amount equal to sixty percent
(60%) (the “Services Fee”) of the net revenues received by DaVinci derived from
performing stem cell transplant therapies on patients at the Lab (the “Net
Revenue”).  Within 15 days following the end of each calendar month, upon
request, DaVinci shall provide Cell Sciences with written reports providing a
detailed accounting of the Net Revenue during such month together with the
Services Fee for such month.  Cell Sciences shall have the right, at its
expense, to inspect and audit the books and records of DaVinci to confirm such
information. 

 

 c.   Vitro shall issue to Frank Cona as CEO of Cell Sciences such number of
shares of a newly declared series of Vitro preferred stock that shall convert,
at the holder’s option, into a total 8,000,000 shares of Vitro common stock. The
certificate of designation for the preferred shares will contain customary
anti-dilution protection for stock splits, dividends and the like.   

d.  In addition, Vitro shall issue to Dr. Scott David as the only other licensed
physician at the DaVinci Center, such number of shares of a newly declared
series of Vitro preferred stock that shall convert, at the holder’s option, into
1,000,000 shares of Vitro common stock (the “David Bonus Shares”).  500,000 of
the David Bonus Shares will vest immediately and the balance will vest on a
monthly basis over a four (4) year period, in accordance with the terms of a
separate Employment Agreement between DaVinci and Dr. Scott David.

 

4.  Vesting.  The Retainer Shares shall vest over a four (4) year period, with
Retainer Shares representing 10,000,000 shares of Vitro Common Stock vesting
upon the execution hereof and with the balance vesting, at a rate of 1/48th of
the total number Retainer Shares not vested upon the execution hereof, per
month.  All Retainer Shares which have vested (the “Vested Shares”) shall not be
subject to the provision of Section 5(c) below.  Notwithstanding anything to the
contrary contained in this Section 4, all unvested Retainer Shares shall
immediately be deemed to be vested in the event that there shall be: (a) a
merger, consolidation or other reorganization of Vitro unless securities
representing more than fifty percent (50%) of the total combined voting  

--------------------------------------------------------------------------------

power of the voting securities of the successor corporation are immediately
thereafter beneficially owned, directly or indirectly and in substantially the
same proportion, by the persons who beneficially owned Vitro outstanding voting
securities immediately prior to such transaction, or (b) the sale, transfer or
other disposition of all or substantially all of Vitro assets, (c) the
acquisition, directly or indirectly by any person or related group of persons of
securities possessing more than fifty percent (50%) of the total combined voting
power of Vitro’s outstanding securities other than in connection with the
financing of the Lab, or (d) Vitro shall terminate this Agreement other than For
Cause, as defined below.

5.   Termination. Except as otherwise expressly provided herein, this Agreement
may be terminated (for purposes of this paragraph 5, Vitro and Cell Sciences
shall be considered as a single party):  

 a.  upon mutual written agreement of the parties, or  

 b.  by the non-defaulting party upon or after the occurrence (but solely upon
or after such occurrence) of any one of the following events (each, an “Event of
Default”): (i) a material breach by the other party of any terms or conditions
of this Agreement which (A) is not corrected within thirty (30) days after
receipt of written notification thereof, if correctable within such thirty (30)
days, or (B) if it is not correctable within such thirty (30) days, the
correction of which is not initiated within such thirty (30) day period and
thereafter diligently pursued until completed; or (ii) one of the parties hereto
shall go into liquidation, a receiver or a trustee appointed for the property or
estate of that party and said receiver or trustee is not removed within one
hundred twenty (120) days, or the party makes an assignment for the benefit of
creditors, whether any of the aforesaid bankruptcy events be the outcome of the
voluntary act of that Party, or  

 c.  Vitro/Cell Sciences may terminate this Agreement “For DaVinci Cause” in the
event that: (i) DaVinci shall commit a material breach of this Agreement which
breach shall remain uncured for a period of thirty (30) days after written
notice by Vitro/Cell Sciences of such breach and such breach has a material
negative effect on the business of the Lab, (ii) DaVinci, or any of its
affiliates, is convicted of any felony or is shown to have engaged in any act of
dishonesty detrimental to Vitro or fraud upon Vitro, or any of its affiliated
companies, or any of its customers, patients or clients, (iii) DaVinci has been
grossly negligent in the performance of his duties or responsibilities and such
breach has a material negative effect on the business of the Lab, or (iv)
DaVinci shall engage in or aid and abet any violation of any US federal or state
securities law.  In the event that Vitro shall terminate this Agreement For
DaVinci Cause, all Retainer Shares which have not vested pursuant to Section 4
above shall be deemed cancelled.  

 d. DaVinci may terminate this Agreement “For Vitro Cause” in the event that:
(i) Vitro/Cell Sciences shall commit a material breach of this Agreement which
breach shall remain uncured for a period of thirty (30) days after written
notice by DaVinci of such breach and such breach has a material negative effect
on the business of the Lab or DaVinci, (ii) Vitro/Cell Sciences, or any of its
affiliates, is convicted of any felony or is shown to have engaged in any act of
dishonesty detrimental to the Lab or DaVinci, or fraud upon DaVinci, or any of
its affiliated companies, or any of its customers, patients or clients, (iii)
Vitro/Cell Sciences has been grossly negligent in the performance of its duties
or responsibilities and such breach has a material negative effect on the
business of the Lab, or (iv) Vitro/Cell Sciences shall engage in or aid and  

--------------------------------------------------------------------------------

abet any violation of any US federal or state securities law.  In the event that
DaVinci terminates this Agreement For Vitro Cause, all Retainer Shares which
have not vested shall be deemed to be immediately vested.  

 In the event of a termination as a result of an Event of Default, the
non-defaulting Party shall be entitled to pursue any remedy provided in law or
equity, including the right to recover any damages it may have suffered by
reason of such Event of Default. Upon a termination of this Agreement, the terms
and conditions of this Agreement that, by their terms, require performance
following the termination or expiration of this Agreement shall survive such  

6.   Inventions.  DaVinci and Vitro shall jointly own all statutory and/or
common law rights to the extent those rights are exercised in the United States;
DaVinci and Cell Sciences  shall jointly own all statutory and/or common law
rights throughout the world outside of the United States.  “Rights” as used
herein means (i) all patents and applications therefor, and all reissues,
divisions, renewals, extensions, provisionals, continuations and
continuations-in-part thereof; (ii) all ideas and inventions (whether or not
patentable or reduced to practice), invention disclosures and improvements, all
trade secrets, proprietary information, know-how and technology; (iii) all works
of authorship, copyrights, and copyright registrations and applications and
(iii) all other forms of technology, including all know-how, show-how, methods,
models, techniques, designs, design rules, network configurations and
architectures, diagrams, documentation, drawings, flow charts, formulae,
algorithms, specifications, routines, subroutines, materials, Software,
procedures, processes, protocols, devices, prototypes, schematics, test
methodologies, software and hardware development tools developed by DaVinci in
connection with the Services provided by DaVinci to Vitro hereunder. 

 

7. Non-Competition.  DaVinci agrees that during the term hereof, DaVinci shall
not establish, create or utilize any other laboratory with regard to obtaining
stem cells for transplant in the Cayman Islands. This non-competition provision
shall not apply to (a) any stem cells provided directly by patients of DaVinci
and (b) any existing relationships that DaVinci has in place for the treatment
of patients as of the date hereof.  Vitro agrees that during the term hereon,
Vitro shall not establish any business which competes with Cell Sciences or
DaVinci in the Cayman Islands. 

 

8.  Representations and Agreements of DaVinci. DaVinci hereby represents,
warrants and covenants with Vitro and Cell Sciences that:  

 

 a.  DaVinci is a corporation duly organized, validly existing, and in good
standing under the laws of the Cayman Islands;  

 

 b.   DaVinci has all requisite corporate power and authority to own, lease, and
operate its properties and its business and to enter into and perform its
obligations hereunder;  

 

 c. The execution, delivery, and performance of this Agreement by DaVinci has
been duly authorized by all requisite corporate action on the part of DaVinci.
This Agreement has been duly executed and delivered by DaVinci and constitutes
the legal, valid and binding obligation of DaVinci, enforceable against DaVinci
in accordance with its terms, except to the extent that enforceability may be
limited by applicable bankruptcy, insolvency, or similar laws affecting the
enforcement of creditors’ rights generally and subject to general principals of
equity; 

--------------------------------------------------------------------------------

 d.  DaVinci agrees to maintain, at its own expense, all legal, governmental and
regulatory approvals, licenses and permits necessary to provide the Services. 

 

 e.  DaVinci’s performance of services will not breach any agreement that
DaVinci has with another party including, without limitation, any agreement to
keep in confidence proprietary information acquired by DaVinci in confidence;  

 

 f.  DaVinci is not and will not be bound by any agreement, nor has assumed or
will assume any obligation, which would in any way be inconsistent with the
services to be performed by DaVinci under this Agreement; and  

 

 g.  DaVinci will perform all services in a professional and workmanlike and
diligent manner.  

 

9.  Representations of Vitro. Vitro hereby represents and warrants to DaVinci
that:

 

 a.  Vitro is a corporation duly organized, validly existing, and in good
standing under the laws of the State of Nevada;  

 

 b.  Vitro has all requisite corporate power and authority to own, lease, and
operate its properties and business and to enter into and perform its
obligations hereunder;  

 

 c.  The execution, delivery, and performance of this Agreement by Vitro have
been duly authorized by all requisite corporate action on the part of Vitro; and
 

 

 d.  This Agreement has been duly executed and delivered by Vitro and
constitutes the legal, valid, and binding obligation of Vitro, enforceable
against Vitro in accordance with its terms, except to the extent that
enforceability may be limited by applicable bankruptcy, insolvency, or similar
laws affecting the enforcement of creditors’ rights generally and subject to
general principles of equity.  

 

10.   Representations of Cell Sciences  Cell Sciences hereby represents,
warrants and covenants with DaVinci that:

 

 a.  Cell Sciences is a corporation duly organized, validly existing, and in
good standing under the laws of the Cayman Islands;  

 

 b.   Cell Sciences has all requisite corporate power and authority to own,
lease, and operate its properties and its business and to enter into and perform
its obligations hereunder;  

 

 c. The execution, delivery, and performance of this Agreement by Cell Sciences
has been duly authorized by all requisite corporate action on the part of Cell
Sciences. This Agreement has been duly executed and delivered by Cell Sciences
and constitutes the legal, valid and binding obligation of Cell Sciences,
enforceable against Cell Sciences in accordance with its terms, except to the
extent that enforceability may be limited by applicable bankruptcy, insolvency,
 

--------------------------------------------------------------------------------

or similar laws affecting the enforcement of creditors’ rights generally and
subject to general principals of equity;

 

 d.  Cell Sciences agrees to maintain, at its own expense, all legal,
governmental and regulatory approvals, licenses and permits necessary to operate
legally wherever it is required to do so. 

 

 e.  Cell Sciences’s performance of services will not breach any agreement that
Cell Sciences has with another party including, without limitation, any
agreement to keep in confidence proprietary information acquired by Cell
Sciences in confidence;  

 

 f.  Cell Sciences is not and will not be bound by any agreement, nor has
assumed or will assume any obligation, which would in any way be inconsistent
with the services to be performed by Cell Sciences under this Agreement; and  

 

 g.  Cell Sciences will perform its duties and obligations in a professional and
workmanlike and diligent manner.  

 

 

 11.  DaVinci Representations Regarding Retainer Shares.  DaVinci hereby
warrants and represents that: 

 

 a.  DaVinci shall receive the Retainer Shares with no current intention of
distributing or reselling the Retainer Shares, the shares of common stock that
the Retainer Shares are convertible into, or any part thereof, or interest
therein, in any transaction which would be in violation of the securities laws
of the United States or any state thereof, without prejudice, however, to the
DaVinci’s rights at all times to sell or otherwise dispose of all or any part of
the Common Stock, under an effective registration statement under the Securities
Act of 1933, as amended (the “Securities Act”), or under an exemption from such
registration requirements available under the Securities Act and applicable
state securities laws.  

 

 b. DaVinci acknowledges that (i) the Retainer Shares have not been registered
under the Securities Act and are being issued to DaVinci by reason of a
transaction exempt from the registration and prospectus delivery requirements of
the Securities Act pursuant to Section 4(2) thereof, (ii) that DaVinci will have
to hold the Retainer Shares and the shares of common stock that the Retainer
Shares are convertible into and bear the economic risk of such investment
indefinitely, unless a subsequent disposition thereof is registered under the
Securities Act or is exempt from such registration and (iii) that Vitro is
issuing a significant number of shares of the same kind and class to other
persons that are important to the success of the planned operation. 

 

 c.  The certificates representing the Retainer Shares shall bear a restrictive
legend in substantially the following form: 

 

"The securities represented by this certificate have not been registered under
the Securities Act of 1933, as amended (the "Securities Act"), and may be
transferred only pursuant to an effective registration statement under the
Securities Act or in

--------------------------------------------------------------------------------

accordance with an applicable exemption from the registration requirements of
the Securities Act."

 

12.  Indemnification. 

 

 a.  Indemnification by Vitro and Cell Sciences. Vitro and Cell Sciences hereby
indemnify, defend, and will hold DaVinci, its Affiliates and their respective
employees, agents, officers and directors (the “DaVinci Indemnified Parties”)
harmless from and against any and all demands, claims, actions, suits,
proceedings, judgments, assessments, costs, expenses, losses, damages,
liabilities, fines, and penalties (including, without limitation, reasonable
attorneys’ fees) (collectively, “Loss”) alleged against or incurred by the
DaVinci Indemnified Parties for property damage or personal injury to the extent
caused by Vitro’s use of the Lab. Vitro and Cell Sciences shall indemnify,
defend, and hold the “DaVinci Indemnified Parties harmless from and against any
and all Third Party Loss alleged against the DaVinci Indemnified Parties by such
Third Party as a result of (a) Vitro’s negligence, professional malpractice or
willful misconduct; or (b) Vitro’s material breach of this Agreement. 

 

 b.  Indemnification by DaVinci. DaVinci shall indemnify, defend, and hold Vitro
and Cell Sciences, their Affiliates and their respective employees, directors,
officers and agents (the “Vitro Indemnified Parties”) harmless from and against
any and all Third Party Loss alleged against any of the Vitro Indemnified
Parties by such Third Party as a result of (i) DaVinci’s negligence,
professional malpractice or willful misconduct; or (ii) DaVinci’ material breach
of this Agreement.  

 

 c.  Procedure for Claims. Each indemnified Party agrees to give the
indemnifying Party prompt written notice of any Loss or discovery of fact upon
which such indemnified Party intends to base a request for indemnification under
Sections 15(a) or 15(b). Each Party shall furnish promptly to the other copies
of all papers and official documents received in respect of any Loss. The
indemnifying Party shall have the sole right to defend, settle, or otherwise
dispose of such Loss, on such terms as the indemnifying Party, in its sole
discretion, shall deem appropriate. The indemnifying Party shall obtain the
written consent of the indemnified Party, which shall not be unreasonably
withheld or delayed, prior to ceasing to defend, settling or otherwise disposing
of any Loss if as a result thereof the indemnified Party would become subject to
injunctive or other equitable relief or any remedy other than the payment of
money, which payment would be the responsibility of the indemnifying Party. The
indemnifying Party shall not be liable for any settlement or other disposition
of a Loss by the indemnified Party which is reached without the written consent
of the indemnifying Party. The reasonable costs and expenses, including
reasonable fees and disbursements of counsel incurred by any indemnified Party
in cooperating with the indemnifying Party in its defense of a Loss, shall be
reimbursed on a quarterly basis by the indemnifying Party, without prejudice to
the indemnifying Party’s right to contest the indemnified Party’s right to
indemnification and subject to refund in the event the indemnifying Party is
ultimately held not to be obligated to indemnify the indemnified Party.  

 

13.   Arbitration.

--------------------------------------------------------------------------------

                        (a)  If the parties hereto are unable, after good faith
negotiations, which each hereby covenants to undertake, to resolve (except as
provided below) any and all disputes in respect to or arising under this
Agreement including, without limitation, in respect to the formation of this
Agreement, or the construction or interpretation of this Agreement, any party
may commence arbitration by sending a written demand for arbitration to the
other party or parties, as provided for in Paragraph. Such demand shall set
forth with particularity and with  supporting detail or documentation the
dispute or matter to be resolved by arbitration.

 

 (b)  There shall be one arbitrator.  If the parties shall fail to select a
mutually acceptable arbitrator  within ten (10) days after the demand for
arbitration is mailed, a single arbitrator shall be appointed as soon as
possible by the ICC Rules of Arbitration or, failing such appointment, pursuant
to the usual procedure of the ICC in such cases.  The fee payable to the
arbitrator shall be based upon the then current fee schedule of the ICC and
shall be advanced one half by each party, upon the written request of the
arbitrator.  

 

                        (c)  The parties shall have the rights of discovery as
authorized by the arbitrator.

 

                        (d)  Except as set forth herein, the arbitrator shall
conduct the arbitration according to the ICC Rules. Arbitration shall take place
in the Cayman Islands unless the parties otherwise agree.  The arbitrator shall
base the decision on the express language of this Agreement.  Within ten (10)
days after the arbitrator is appointed, or as soon thereafter as shall be
reasonably practicable, a hearing with respect to the dispute or matter to be
resolved shall be conducted by the arbitrator.  Each party may make written
submissions to the arbitrator, and  each party shall have a reasonable
opportunity for rebuttal, but no longer than ten (10) days.  As soon as
reasonably practicable, but not later than forty five (45) days (barring exigent
circumstances) after the hearing is completed, the arbitrator shall arrive at a
final decision, which shall be reduced to writing, signed by the arbitrator and
mailed to each of the parties and their legal counsel.

 

                        (e)  All decisions of the arbitrator shall be  final,
binding and conclusive on all parties, and (except as provided below) shall
constitute the only method of resolving  disputes or matters subject to
arbitration pursuant to this  Agreement.  Judgment may be entered upon such
decision in accordance with applicable law in any court having jurisdiction  

thereof.

 

                        (f)  This arbitration clause and all rulings or
decisions of the arbitrator shall be specifically enforceable in  a court of
law, or the arbitral tribunal.

 

 

14. Miscellaneous.  

 

 a.  Assignment. This Agreement shall be binding upon and shall inure to the
benefit of the Parties hereto and their respective successors and permitted
assigns. This Agreement shall not be assignable by either Party without the
prior written consent of the other Party.  

 

 b.  Expenses. Except for payments expressly required to be made by Vitro
hereunder, each Party shall bear its own expenses with respect to the
transactions contemplated by  

--------------------------------------------------------------------------------

this Agreement, including, without limitation, its attorneys’ fees and other
expenses related to the preparation and execution of this Agreement and the
completion of this Agreement.

 

 c.  Severability. Each of the provisions contained in this Agreement shall be
severable, and the unenforceability of one shall not affect the enforceability
of any others or of the remainder of this Agreement.  

 

 d.  Amendment. This Agreement may not be amended, supplemented or otherwise
modified except by an instrument in writing signed by both Parties hereto.  

 

 e.  Waiver. The failure of any Party to enforce any condition or part of this
Agreement at any time shall not be construed as a waiver of that condition or
part, nor shall it forfeit any rights to future enforcement thereof.  

 

 f.  Governing Law. This Agreement shall be construed and enforced in accordance
with and governed by the laws of Grand Cayman, excluding the conflicts of laws
and provisions thereof.  

 

 g.  Headings. The headings of the sections and subsections of this Agreement
are inserted for convenience only and shall not be deemed to constitute a part
hereof.  

 

 h.  Counterpart. The Parties may execute this Agreement in one or more
counterparts, and each fully executed counterpart shall be deemed an original.  

 

 i.  Notices. All notices and consents hereunder shall be in writing, effective
upon receipt, and shall be delivered personally, mailed by registered or
certified mail (return receipt requested, postage prepaid), or sent by express
courier service, to the other Party at the following addresses (or at such other
address for a Party as shall be specified by like notice):  

 

 To DaVinci: 

 

 To Vitro: 

 

 To Cell Sciences: 

 

 All notices and consents provided for herein shall become effective: (a) on
delivery if given in person; or (b) two (2) business days after delivery to the
overnight service.  

 

 j.  Entire Agreement. This Agreement constitutes the entire and exclusive
agreement between the Parties with respect to the subject matter herein, and
supersede all prior and contemporaneous communications and understandings
between the Parties, written or oral, relating to this subject matter. This
Agreement may only be amended in a writing executed by an authorized
representative of each Party.  

 

 k.  Relationship of Parties. The status of the Parties under this Agreement
shall be that of independent contractors. Neither Party shall have the right to
enter into any agreements on  

--------------------------------------------------------------------------------

behalf of the other Party, nor shall it represent to any person that it has any
such right or authority. Nothing in this Agreement shall be construed as
establishing a partnership or joint venture relationship between the Parties.
Neither Party shall have authority to enter into contracts or binding
commitments in the name or on behalf of the other Party. Neither Party will use
the other Party’s logo or marks without prior written approval, and then such
use shall be only for the benefit of the other Party and at the direction of the
other Party. Neither Party shall be, nor represent itself as being, an agent of
the other Party, and shall not be, nor represent itself as being, authorized to
bind the other Party. Each Party agrees, acknowledges and understands that
neither it nor its employees or agents shall have the status of an employee of
the other Party and shall not participate in any employee benefit plans or group
insurance plans or programs (including, but not limited to salary, bonus or
incentive plans, stock option or purchase plans, or plans pertaining to
retirement, deferred savings, disability, medical or dental), even if it is
considered eligible to participate pursuant to the terms such plans. In
addition, each Party understands and agrees that consistent with its independent
contractor status, neither it nor its employees or agents will apply for any of
the other Party’s government-sponsored benefits intended only for employees,
including, but not limited to, unemployment benefits. Such Party’s exclusion
from benefit programs maintained by the other Party is a material component of
this Agreement. To the extent a Party or its employees or agents may become
eligible for any benefit programs maintained by the other Party (regardless of
timing or reason for eligibility), such Party hereby waives its right to
participate in the programs. Each Party shall defend, indemnify and hold the
other Party harmless from any and all claims made by its personnel on account of
an alleged failure by the other Party to satisfy any tax or withholding
obligations.

 

 l.  Compliance with Laws. Each Party will comply with all applicable laws,
rules, ordinances and regulations of any governmental entity or regulatory
agency governing the actions to be taken and provided hereunder. Neither Party
will take any action in violation of any applicable law, rule, ordinance or
regulation that could result in liability being imposed on the other Party.  

 

 m.  Confidentiality. Each Party agrees that all information observed,
communicated or otherwise disclosed to it by the other Party in connection with
this Agreement (which information shall at all times be the property of the
Party communicating such information) shall constitute “Confidential
Information” and be subject to the confidentiality obligations and other
provisions of this Agreement.  

 

 

 

 

[SIGNATURES ON FOLLOWING PAGE]

--------------------------------------------------------------------------------

DAVINCI CENTRE FOR WELLNESS AND ALTERNATIVE THERAPIES

 

 

By:  /s/ Lorraine Cona

Lorraine Cona, CEO/Director

 

 

VITRO DIAGNOSTICS, INC.

 

 

By:  /s/ James Musick

James Musick, PhD, President and CEO

 

HALO CELL SCIENCES LTD

 

By:  /s/ James Musick

James Musick, Director